作者:Rui Ding、Ting Zhang、Jiashu Xie、Jessica Williams、Yihong Ye、Liqiang Chen
DOI:10.1016/j.bmcl.2016.09.068
日期:2016.11
promising strategy for cancer therapy. Eeyarestatin I (EerI) blocks p97 through a novel mechanism of action and has favorable anti-cancer activities against cultured cancer cells. However, its poor aqueous solubility severely limits its in vivo applications. To circumvent this problem, we have identified EerI derivatives that possess improved aqueous solubility by introducing a single solubilizing group. These
已证实抑制p97(也称为含valosin的蛋白质(VCP))是一种有前途的癌症治疗策略。Eeyarestatin I(EerI)通过一种新的作用机制阻断p97,并对培养的癌细胞具有良好的抗癌活性。但是,其差的水溶性严重地限制了其体内应用。为了解决这个问题,我们已经确定了通过引入单个增溶基团而具有改善的水溶性的EerI衍生物。这些修饰的化合物保留了内质网(ER)的压力诱导和抗增殖活性,以及通常良好的体外代谢特性,表明这些EerI衍生物可作为进一步优化的候选对象。